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Respiratory syncytial virus infection in children with 
congenital heart disease: global data and interim 
results of Korean RSV-CHD survey
Respiratory syncytial virus (RSV) is a main cause of hospitalization 
for bronchiolitis and pneumonia in infants worldwide. Children with 
hemodynamically significant congenital heart disease (HS-CHD), 
as well as premature infants are at high risk for severe RSV diseases. 
Mortality rates for CHD patients hospitalized with RSV have been 
reported as about 24 times higher compared with those without RSV 
infection. Recently with advances in intensive care, mortality rates in 
CHD patients combined with RSV have decreased below 2%. The 
requirements of intensive care and mechanical ventilation for CHD 
patients with RSV infection were still higher than those without RSV 
infection or with non-CHD children. RSV infection has frequently 
threatened CHD infants with congestive heart failure, cyanosis, or 
with pulmonary hypertension. As a progressive RSV pneumonitis in 
those infants develops, the impairment of oxygen uptake, the breathing 
workload gradually increases and eventually causes to significant 
pulmonary hypertension, even after the operation. Preventing RSV 
infection as much as possible is very important, especially in infants 
with HS-CHD. A humanized monoclonal antibody, palivizumab, 
has effective in preventing severe RSV disease in high-risk infants, 
and progressive advances in supportive care including pulmonary 
vasodilator have dramatically decreased the mortality (<1%). 
Depending on the global trend, Korean Health Insurance guidelines 
have approved the use of palivizumab in children <1 year of age with 
HS-CHD since 2009. Korean data are collected for RSV prophylaxis in 
infants with CHD. 
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Introduction 
Respiratory syncytial virus (RSV) is the most common cause of 
lower respiratory tract infection in infants and toddlers worldwide, 
including Korea. According to the biweekly reports of Korea Centers 
for Disease Control and Prevention, the seasonal outbreaks of RSV 
infection occur during the winter months, September through 
March, even in Korea. Almost all children have RSV infection 
until the age of 2 years, and nearly half of those will be infected two 
episodes on the average1-3). About half the children may develop 
bronchiolitis and pneumonia which might require hospitalization. 
Often for some cases, an intensive care with mechanical ventilation 
is necessary. RSV infection in particular pediatric groups produces 
significant morbidity and mortality: especially in premature 
infants with <35 weeks gestational age and in patients with chronic 
lung disease, such as bronchopulmonary dysplasia (BPD) or 
hemodynamically significant congenital heart disease (HS-CHD)4,5).
CHD patients with RSV infection were more likely to be 
hospitalized, and had greater morbidity and mortality associated with 
bronchiolitis than non-CHD infants, particularly associated with 
undertaking corrective surgery in CHD patients with a history of 
recent RSV bronchiolitis. In Korea, there were a few of initial reports 
for intervening in serious and fatal cases with CHD superimposed by 
RSV infection, and those still remains as painful memories for some 
pediatric cardiologists4-6). For the past 10 years, with advances in 
operative skills as well as transcatheter intervention and intensive care, 
RSV prophylaxis with palivizumab were introduced for these high-
risk infants7,8). This review is to describe about the impact of RSV 
infection on infants with CHD and the recent trends according to 
global and Korean standardization. 
Impact of Respiratory Syncytial virus on infants 
with he modynamically significant congenital heart 
diseases 
Lung compliance and airway resistance contributes to how 
much effort a patient needs for breathing. The airways of infants 
have greater resistance compared with the older children due to 
their smaller diameter. Increased peripheral resistance affects the 
distribution of air ventilation, and makes infants more vulnerable to 
hypoxemia. Spontaneous ventilation is characterized by a functional 
residual capacity, that is relatively small in infants and then the infant 
is prone to potential ventilation-perfusion mismatch and is at higher 
risk for respiratory compromise5,9-12).
Depending upon the types of cardiac defect which is present, 
the lung of the infant may be over-circulated, as in the setting of 
ventricular septal defect, or under-circulated as with tetralogy of 
Fallot with pulmonary stenosis9,10). 
Pulmonary over-circulation associated with left-to-right shunting 
may result in mucosal edema, and luminal narrowing, as well as 
vascular or cardiac compression of the large bronchuses. During the 
typically delayed transition of the circulation in infant with CHD, 
usually occurring within the first few months, decreased pulmonary 
arteriolar resistance leads to increasing left-to-right shunt (LR shunt). 
There is a decrease in lung compliance and an increase in respiratory 
rate. Infants also may have significantly increased pulmonary blood 
flow, capillary wedge pressure and left atrial pressure. The result may 
be pulmonary edema, which leads to further decreases in functional 
residual capacity, potentiating ventilation-perfusion mismatch and 
become susceptible to hypoxia. In addition increased alveolar edema 
will lead to decreased lung volume and decreased compliance of the 
lung bed9,12).
 In the under-circulated lung, as seen with right-to-left shunting, 
those patients with cyanotic congenital heart disease typically include 
tetralogy of Fallot. The basic physiology is obstruction to pulmonary 
outflow due to stenosis. These patients are prone to increased 
hypoxemia because the degree of pulmonary stenosis increases over 
time, and there may be reduced lung volume and airway hypoplasia. 
Where there is increased ventilation compared with perfusion, dead 
space ventilation may lead to further hypoxemia. With decreased 
alveolar saturation, compliance of the lungs may be increased. 
However, small airway obstruction may also be present, leading to 
increase airway resistance. At baseline, these cyanotic patients are 
at risk for increasing hypoxemia, and RSV infection can precipitate 
significant cyanosis5,9).
Many infants with complex CHD have both manifestations of 
cyanosis and relatively increased pulmonary blood flow. Examples 
of such patients include those with most forms of single ventricle 
including hypoplastic left heart syndrome and hypoplastic right heart 
of tricuspid atresia, or pulmonary atresia. The majority of infants 
with complex univentricular heart will have undergone palliative 
surgery early period with risk of increasing ventilation-perfusion 
mismatch, which is potentiated by RSV infection. Compromised 
ventricular function may contribute to higher pulmonary venous 
pressures, which may lead to capillary leak and pulmonary edema. In 
addition, those patients with oxygen saturations 85% have a relatively 
large amount of pulmonary blood flow, which can contribute to 
risk for respiratory complications in this setting. The result of this 
mixed physiology may be the reason for the poor tolerance in a 
superimposed respiratory infection, such as with RSV5,9,10,12). 
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Global Trends of Respiratory Syncytial virus 
infection with congenital heart diseases 
The development of the recent innovative interventions is expected 
to change RSV infection treatment in infants with CHD. Earlier 
studies in RSV infection on CHD patients revealed that lower 
respiratory infection by RSV was potentially lethal leading to 
increased mortality and morbidity in HS-CHD infants1-6,12). 
On the effects of RSV infection during late 1970’s in infants with 
CHD reported in 1982, the severity of RSV bronchiolitis in children 
with CHD for a hospital based cohort study of all infants (n=699) 
was significantly greater than those without CHD, categorized by 
those who require intensive care (63% vs. 14%, P<0.001) and assisted 
ventilation (22% vs. 5%, P<0.01). These fatality rate was higher in 
the CHD group (37% vs. 1.5%, P<0.01). In infants with RSV and 
pulmonary hypertension, the mortality rate was extraordinarily high 
(73%)4). In these subgroup, nosocomial infection was associated 
with mortality rate, compared with children without CHD (44% vs. 
5%)4). 
A review in Canada between 1988 and 1991 was evaluated for 260 
children with CHD, hospitalized with RSV disease at 12 pediatric 
tertiary care centers, and 87 (33%) required intensive care and 49 
(19%) required mechanical ventilation13). Other reports released in 
1992 and 1995 revealed that pulmonary hypertension in particular 
was the single most important factor in causing severe RSV infection 
in infants with CHD14). 
The morbidity caused by RSV infection in children with CHD 
correlates with the severity of the underlying cardiac disease, 
represented by the degree of compromise of the baseline functional 
status in cardio-pulmonary system, pulmonary flow/ventilation 
mechanics, degree of cyanosis, level of pulmonary hypertension and 
extent of ventilation/perfusion mismatch14,15).
In 1990 through 1995, a retrospective review for 25 infants 
with CHD showed that RSV bronchiolitis and pneumonia causes 
substantial morbidity and even mortality in the immediate period 
sur rounding either palliative or corrective cardiac surgery15). Car-
diac surgery performed during symptomatic RSV bronchiolitis 
and pneumonia is associated with a high risk of postoperative 
complications. In particular, postoperative pulmonary hypertension 
can cause immediate postoperative mortality. These complications 
in CHD patients appeared to occur more frequently and sometimes 
fatal in patients who had undertaken earlier surgery, while bronc-
hiolitis due to RSV infection continues as compared with those who 
had later surgery. Therefore, to obtain complete and safe results after 
congenital heart surgery, procedures should not be performed in an 
infant who has not fully recovered from an acute RSV infection. 
In addition, RSV is also an important cause of postoperative 
noso comial infection. It may be due to a transient immunologic 
dysfunction following cardiopulmonary bypass and a possibility for 
dilution of serum neutralizing antibodies. Preoperative screening for 
asymptomatic RSV infection has been suggested as a main key to 
reduce this morbidity. This was the basic idea in the development of 
RSV vaccination, to prevent severe RSV infection in high-risk infants 
12,14,15).
For recent 10 years with advances in intensive care, mortality rates 
in CHD patients combined with RSV has decreased to below 2% 
of the population11,12). Nevertheless the requirements of intensive 
care for CHD patients with RSV infection in progress, were much 
higher as almost 2.5 times compared with those without current 
RSV infection, and as up to 1.7 times than those for non-CHD 
children with RSV infection. The need of mechanical ventilation for 
RSV infection in CHD patients was recognized as about 2.4 times 
higher than in non-CHD patients1,4-6,12). This infection is further 
threatening to particular conditions of CHD patients: infants with 
congestive heart failure, cyanosis, or pulmonary hypertension. 
Under these cardiac conditions there are severely restricted capacity 
of cardiac function to increase cardiac output and oxygen delivery. 
As RSV pneumonitis progresses in those infants with compromised 
cardiac performance, oxygen uptake was markedly impaired and the 
work of breathing was gradually increased5,14,15).
Non-sustained immunity and difficulties to develop the effective 
vaccines made RSV management directed toward a passive im-
munotherapy for these high risk children16-18). Palivizumab is one 
of the first humanized murine monoclonal antibody targeting 
the RSV envelope F glycoprotein, and in a Phase III clinical trial 
palivizumab through randomized double-blind study of 1,287 
patients from 1998, significantly reduced RSV hospitalization 
in children with HS-CHD safely8). Study results showed a 45% 
relative reduction in RSV hospitalization among children receiving 
palivizumab prophylaxis (9.7% vs. 5.3%, P=0.003). Other 
information was that serum palivizumab levels were reduced to 58% 
after cardiopulmonary bypass due to diluted effect. The American 
Academy of Pediatrics (AAP) revised its indications for palivizumab 
to include less than 24 month aged children with HS-CHD in 
200319). In addition, the AAP recommended redosing of CHD 
patients following cardiopulmonary bypass to reach adequate serum 
concentration of neutralizing antibody to protect the vulnerable 
postoperative infant. Many countries including Japan have followed 
their own guidelines that identify high-risk patients and define the 
appropriate timing of vaccination, usually 5 doses during winter19-23). 
Its guidelines for CHD patients in Japan were approved for children 
less than 24 month of age at the start of RSV season in October 2005 
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similar to those of AAP22). 
However, RSV hospitalization has not been eliminated in CHD 
patients receiving prophylaxis, as palivizumab tends to attenuate 
but not eradicate RSV disease21-25). Significant controversy remains 
regarding the cost effectiveness of palivizumab prophylaxis in high-
risk patients, including those with CHD25,26). Eventually this may be 
considered as the limitation of passive immunization. 
Even subsequent studies have a decreasing trend in mortality, 
both medical and surgical morbidity, e.g. RSV hospitalization 
requiring intensive care and oxygen supply and need for mechanical 
ventilation, caused by RSV remain significant high though it varies 
with the degree of cardiac compromise21,22,24,25). In infant with HS-
CHD, major issues by result of RSV infection are considered as the 
compromised cardio-pulmonary function during perioperative 
period, caused by pulmonary hypertension, bi-ventricular functional 
failure, and deoxygenation. Recently as to the development of 
intensive care, including brand-new mechanical ventilation and 
selective pulmonary vasodilators, it looks impossible to make the 
treatment available even in serious RSV infected infants5).
The chronic effects of RSV infection on lung are not only confined 
to acute morbidity, but there may also be long-term sequelae5,9). A 
long-term prospective study for 7.5 years, provide strong evidence 
that RSV bronchiolitis in infancy is associated with a higher risk 
of developing subsequent bronchial obstructive disease in the 
development of asthma and allergy at least in some children. 
Korean experiences of Respiratory Syncytial virus 
infection with congenital heart diseases 
Similarly in Korea, there were a few of initial reports for intervening 
in serious and fatal cases with CHD superimposed by RSV 
infection, and still remains as a painful memories for some pediatric 
cardiologists27). According to a Korean study reported in 2010, 76 
children with 45 CHD and 31 non-CHD patients infected by RSV 
were evaluated, just before palivizumab era, from 2003 to 200627). 
Of total 71 patients, 22 (48.9%) were treated in intensive care in 3 of 
non-CHD patients (9.7%), 12 (26.7%) were required mechanical 
ventilation but none in non-CHD patients, and 2 (4.4%) mortalities 
of CHD patients were noticed none in non-CHD patients. 
Korean public health insurance guidelines recommend the use 
of palivizumab in children less than 1 year of age with HS- CHD 
since 2009. The categories of theses HS-CHD include pulmonary 
hypertension, cyanotic heart diseases, and CHD treated by 
medication for congestive heart failure. 
Since palivizumab was introduced to premature infants of Korea 
in 2007, the total number of infants receiving palivizumab has 
more than doubled annually. A preliminary survey for pediatric 
cardiologists done after 2009 RSV season revealed that 40% thought 
that palivizumab was quite effective; another 40% thought that it 
may be effective in Korea. In addition, about 1.8 doses of palivizumab 
were used in limited pediatric centers. Current data has been collected 
on the effectiveness of RSV prophylaxis with palivizumab in infants 
with CHD in Korea. 
Conclusion 
Infants with CHD represent a group that is at a higher risk for 
morbidity from RSV infection. RSV infection is further threatening 
to particular conditions of CHD patients: infants with congestive 
heart failure, cyanosis, or pulmonary hypertension. Under these 
cardiac conditions, CHD patients are severely restricted in capacity 
of cardiac function to increase cardiac output and oxygen delivery. 
As RSV pneumonitis progresses in those infants with compromised 
cardiac performance, oxygen uptake is markedly impaired and the 
work of breathing is gradually increased. 
A few reports of RSV experiences in Korea were similar to those 
of global data. Eventhough fatal cases with CHD superimposed 
by RSV infection are still under concern, RSV prophylaxis using 
palivizumab and powerful advances in intensive care has been shown 
to reduce RSV mortality and morbidity in infants with HS CHD, 
particularly those with palliated complex disease, unrepaired serious 
CHD and those with significant residual defects after cardiac surgery.
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